Is Merck Paying Peanuts to Viralytics for Full Access to Its Oncolytic Immunotherapy Drug Candidate?
The Merck DealThe competition between the leading checkpoint inhibitor cancer drugs Opdivo/Yervoy (Bristol Myers Squibb Co (BMY US) ) and Keytruda...
270 Views
Nektar: New Pathways To Smarter Deals?
Nektar Therapeutics (NKTR US) 's share price soared 11.02% to $84 on Wednesday after it announced the world's largest ever biotech deal with...
254 Views
Genomics as an Investment Theme
Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...
318 Views
Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017
Daiichi Sankyo [DSK] (4568 JP) released Phase I data for DS-8201 at ESMO 2017 as follows: 32% overall response rate, 82% disease control rate. The...
158 Views
Biosimilar Battlefield: Samsung Bioepis Forecast
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
516 Views